These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 30246955)

  • 41. [Tumor markers in melanoma].
    Morsches B; Prellwitz W; Benes P; Schramm P; Trumpfheller R; Korting GW
    Dermatol Monatsschr; 1984; 170(6):380-90. PubMed ID: 6205909
    [No Abstract]   [Full Text] [Related]  

  • 42. Cluster analysis of serum proteins in malignant cutaneous melanoma: search for disease markers.
    Ragazzi E; Vogliardi S; Allegri G; Costa CV; Lise M; Rossi CR; Seraglia R; Traldi P
    Rapid Commun Mass Spectrom; 2003; 17(13):1511-5. PubMed ID: 12820221
    [No Abstract]   [Full Text] [Related]  

  • 43. Plasma 25-hydroxyvitamin D and risk of non-melanoma and melanoma skin cancer: a prospective cohort study.
    Afzal S; Nordestgaard BG; Bojesen SE
    J Invest Dermatol; 2013 Mar; 133(3):629-636. PubMed ID: 23190899
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients.
    Domingo-Domènech J; Castel T; Auge JM; Garcia-Albeniz XA; Conill C; Puig S; Vilella R; Matas J; Malvehy J; Gascón P; Mellado B; Molina R
    Tumour Biol; 2007; 28(5):264-72. PubMed ID: 17962723
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma.
    Hoejberg L; Bastholt L; Johansen JS; Christensen IJ; Gehl J; Schmidt H
    Melanoma Res; 2012 Aug; 22(4):287-93. PubMed ID: 22617301
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quantitative detection of soluble adhesion molecules in sera of melanoma patients correlates with clinical stage.
    Schadendorf D; Diehl S; Zuberbier T; Schadendorf C; Henz BM
    Dermatology; 1996; 192(2):89-93. PubMed ID: 8829517
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Analysing the serum levels of tumour markers and primary tumour data in stage III melanoma patients in correlation to the extent of lymph node metastases--a prospective study in 231 patients.
    Neuss H; Koplin G; Raue W; Reetz C; Mall JW
    Acta Chir Belg; 2011; 111(4):214-8. PubMed ID: 21954736
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum levels of glycoprotein Dickkopf-1 in patients with cutaneous malignant melanoma: a prospective pilot study.
    Feldmann R; Schierl M; Fink AM; Sator PG; Maiweg J; Steiner A
    Dermatology; 2011; 222(2):171-5. PubMed ID: 21389688
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum levels of hepatocyte growth factor as a potential tumor marker in patients with malignant melanoma.
    Hügel R; Muendlein A; Volbeding L; Drexel H; Richtig E; Wehkamp U; Painsi C; Lange-Asschenfeldt B; Hauschild A; Egberts F
    Melanoma Res; 2016 Aug; 26(4):354-60. PubMed ID: 27206057
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
    Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
    J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Decreased serum microRNA-206 level predicts unfavorable prognosis in patients with melanoma.
    Tian R; Liu T; Qiao L; Gao M; Li J
    Int J Clin Exp Pathol; 2015; 8(3):3097-103. PubMed ID: 26045823
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [S-100B and MIA (melanoma inhibiting activity) serum proteins: a prospective study of their value as melanoma progression markers].
    Dornier C; Dousset B; Legras B; Barbaud A; Schmutz JL
    Ann Dermatol Venereol; 2002 May; 129(5 Pt 1):739-40. PubMed ID: 12124520
    [No Abstract]   [Full Text] [Related]  

  • 53. Stathmin is a potential therapeutic target but not a prognostic marker in melanoma: an immunohistochemical study of 323 melanocytic lesions.
    Dundr P; Simon K; Němejcová K; Bártů M; Tichá I; Michálková R; Jakša R; Věcková Z; Kodet O
    Melanoma Res; 2019 Apr; 29(2):157-162. PubMed ID: 30422880
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serum miR-16: A Potential Biomarker for Predicting Melanoma Prognosis.
    Guo S; Guo W; Li S; Dai W; Zhang N; Zhao T; Wang H; Ma J; Yi X; Ge R; Wang G; Gao T; Li C
    J Invest Dermatol; 2016 May; 136(5):985-993. PubMed ID: 26829037
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients.
    Weinlich G; Murr C; Richardsen L; Winkler C; Fuchs D
    Dermatology; 2007; 214(1):8-14. PubMed ID: 17191041
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metastatic volume: an old oncologic concept and a new prognostic factor for stage IV melanoma patients.
    Panasiti V; Curzio M; Roberti V; Lieto P; Devirgiliis V; Gobbi S; Naspi A; Coppola R; Lopez T; di Meo N; Gatti A; Trevisan G; Londei P; Calvieri S
    Dermatology; 2013; 227(1):55-61. PubMed ID: 24008289
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Correlation between insulin-like growth factor binding protein-3 serum level and melanoma progression.
    Panasiti V; Naspi A; Devirgiliis V; Curzio M; Roberti V; Curzio G; Gobbi S; Calvieri S; Londei P
    J Am Acad Dermatol; 2011 May; 64(5):865-72. PubMed ID: 21429618
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serological response to human endogenous retrovirus K in melanoma patients correlates with survival probability.
    Hahn S; Ugurel S; Hanschmann KM; Strobel H; Tondera C; Schadendorf D; Löwer J; Löwer R
    AIDS Res Hum Retroviruses; 2008 May; 24(5):717-23. PubMed ID: 18462078
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma.
    Abraha HD; Fuller LC; Du Vivier AW; Higgins EM; Sherwood RA
    Br J Dermatol; 1997 Sep; 137(3):381-5. PubMed ID: 9349333
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [A comparison of the morphofunctional characteristics of the peripheral blood lymphocytes and the immune status of patients with malignant melanoma of the skin].
    Naleskina LA; Ganina KP; Labunets IF; Grinevich IuA; Abramenko VA
    Tsitol Genet; 1996; 30(5):16-22. PubMed ID: 9026985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.